Celcuity is a clinical-stage biotechnology company developing targeted therapies for solid tumors, with its lead candidate gedatolisib, a multi-kinase inhibitor that comprehensively targets the PI3K/AKT/mTOR pathway across multiple components. The company is advancing gedatolisib in clinical trials for hormone receptor-positive breast cancer and prostate cancer, with regulatory applications pending for breast cancer indications; if approved, Celcuity plans to commercialize the drug independently or through partnerships in the U.S. and select international markets. The company operates under a licensing agreement with Pfizer requiring milestone payments and tiered royalties, with revenue potential tied to gedatolisib's market adoption in a multi-billion-dollar addressable market for advanced breast cancer.